The use of dulaglutide in real clinical practice in patients with type 2 diabetes mellitus in Moscow

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. Evaluation of the effectiveness of dulaglutide in real clinical practice for patients with type 2 diabetes mellitus (DM2) in Moscow.

Methods. To assess the main indicators of DM2 patients using dulaglutide in therapy, a sample was formed from the Moscow segment of the Federal Register of Diabetes Mellitus (FRDM) as of 02/14/2024. To assess the effectiveness of dulaglutide therapy over a 5-year follow-up period, an additional sample of patients from the Moscow segment of the FRDM who began treatment with dulaglutide in 2018 was formed.

Results. When assessing the dynamics of carbohydrate metabolism control indicators over a more than 5-year follow-up period (2018–02/01/2024), a trend towards a decrease in HbA1c levels from 7.3 to 7.0% was noted (p>0.05). In the subgroup of patients who did not receive insulin therapy, a statistically significant decrease in HbA1c levels from 7.3 to 6.7% was demonstrated (p=0.04); there was no statistically significant change in HbA1c levels on insulin therapy (7.5±1.1 versus 7.7±1.1%; p>0.05). When assessing the dynamics, a statistically significant decrease in body weight from 102.9±21.8 to 98.4±19.6 kg, a decrease in body mass index (BMI) from 35.6 to 33.5 kg/m2 (p<0.05) primarily in patients who did not receive insulin therapy (p<0.05) was noted. In patients on insulin therapy, there were no statistically significant differences in the dynamics of body weight and BMI.

Conclusion. The use of dulaglutide in real clinical practice demonstrates long-term maintenance of glycemic control indicators within or close to target values and a statistically significant reduction in body weight and BMI. The greatest effectiveness in achieving glycemic control, reducing body weight and BMI was achieved in a cohort of DM2 patients not receiving insulin medications.

Full Text

Restricted Access

About the authors

M. B. Antsiferov

Endocrinological Dispensary of the Moscow Healthcare Department

Email: koala58@mail.ru
ORCID iD: 0000-0002-9944-2997
SPIN-code: 1035-4773
Russian Federation, Moscow

D. M. Antsiferova

Endocrinological Dispensary of the Moscow Healthcare Department; Russian Medical Academy of Continuous Professional Education

Email: koala58@mail.ru
ORCID iD: 0000-0002-3920-5914
Russian Federation, Moscow; Moscow

O. M. Koteshkova

Endocrinological Dispensary of the Moscow Healthcare Department

Author for correspondence.
Email: koala58@mail.ru
ORCID iD: 0000-0001-8428-4116
SPIN-code: 6141-1224

Cand. Sci. (Med.), Head of the Department of Education and Treatment of Diabetes

Russian Federation, Moscow

N. A. Demidov

City Hospital of Moscow City of the Moscow Healthcare Department

Email: koala58@mail.ru
ORCID iD: 0000-0001-8289-0032
SPIN-code: 7715-4508
Russian Federation, Moscow

References

  1. www. diabetesatlas.org. Facts & figures (idf.org) URL: https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html
  2. Анциферов М.Б., Демидов Н.А., Калашникова М.Ф. и др. Динамика основных эпидемиологических показателей у пациентов с сахарным диабетом, проживающих в Москве (2013–2018). Сахарный диабет. 2020;23(2):113–24. [Antsiferov M.B., Demidov N.A., Kalashnikova M.F. and others. Dynamics of the main epidemiological indicators in patients with diabetes mellitus living in Moscow (2013–2018). Diabetes mellitus. 2020;23(2):113–24. (In Russ.)]. doi: 10.14341/DM11374.
  3. American Diabetes Association. Diab Care. 2023;46(Suppl. 1):S1–298.
  4. Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы диагностики и лечения сахарного диабета. Сахарный диабет. 2023;26(Suppl. 2):1–231. [Dedov I.I., Shestakova M.V., Mayorov A.Yu. Algorithms for the diagnosis and treatment of diabetes mellitus. Diabetes mellitus. 2023;26(Suppl. 2):1–231. (In Russ.)]. doi: 10.14341/DM13042.
  5. Nauck M.A., Quast D.R., Wefers J., Meier J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Mol Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102.
  6. Shyangdan D.S., Royle P., Clar C., et al. Glucagon-like peptide analogues for type 2 diabetes malloitus. Cochrane Database Syst. Rev. 2011;2011:CD006423. doi: 10.1002/14651858.CD006423.pub2.
  7. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diab Obes Metab. 2016;18(3):203–16. doi: 10.1111/dom.12591.
  8. Frias J.P., Bonora E., Nevarez Ruiz L., et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diab Care. 2021;44:765–73. Doi: 10.2337/ dc20-1473.
  9. Gerstein H.C., Colhoun H.M., Dagenais G.R., et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30. doi: 10.1016/S0140-6736(19)31149-3.
  10. Botros F.T., Gerstein H.C., Malik R., et al. Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis. Diab Care. 2023;46(8):1524–30. doi: 10.2337/dc23-0231.

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Dynamics of the number of DM2 patients according to the data of the Moscow segment of FRDM from 2008 to 2023 (thousand people)

Download (185KB)
3. Fig. 2. Dynamics of CVD incidence in patients with DM2 according to the Moscow segment of FRDM, 2013-2023

Download (108KB)
4. Fig. 3. Dynamics of the use of traditional oral sugar-lowering drugs in patients with DM2 (% of patients) according to the data of the Moscow segment of the FRDM, 2016-2023

Download (90KB)
5. Fig. 4. Dynamics of the use of modern sugar-lowering drugs in the therapy of DM2 (52.3% as of 01.01.2024) according to the data of the Moscow segment of the FRDM, 2016-2023

Download (97KB)
6. Fig. 5. Dynamics of the number of DM2 patients receiving dulaglutide according to the Moscow segment of the FRDM from 2016 to 2023

Download (44KB)
7. Fig. 6. Dynamics of HbA1c level in DM2 patients who received dulaglutide since 2018 (n=49)

Download (72KB)
8. Fig. 7. BMI dynamics in DM2 patients who received dulaglutide since 2018. (n=49)

Download (79KB)

Copyright (c) 2024 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies